Paper Details

  1. Home
  2. Paper Details

Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.

Author: AiJing, EisingerDominic, LaBrieSamuel T, MedvedevaIrina V, SchaferPeter, StokesMatthew E, TrotterMatthew W B, YangRobert

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study presents the largest plasma proteomic biomarker dataset available from apremilast clinical trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis. In psoriasis patients, IL-17A and KLK-7 were identified as biomarkers for disease severity and apremilast pharmacodynamic effect. Combined decline rate of KLK-7, PEDF, MDC, and ANGPTL4 was associated with responders. In ankylosing spondylitis, IL-6 and LRG-1 were identified as biomarkers for disease severity.
Paper Details　
Original Abstract of the Article :
Finding biomarkers that provide shared link between disease severity, drug-induced pharmacodynamic effects and response status in human trials can provide number of values for patient benefits: elucidating current therapeutic mechanism-of-action, and, back-translating to fast-track development of ne...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969165/

データ提供：米国国立医学図書館（NLM）

Unveiling the Secrets of Apremilast: A Biomarker-Driven Approach

This study delves into the fascinating world of [biomarkers] and their role in [drug development] and [personalized medicine]. The authors present the largest plasma proteomic biomarker dataset to date, analyzing data from clinical trials of [apremilast], a phosphodiesterase type 4 inhibitor, in patients with [psoriasis (PSOR), psoriatic arthritis (PsA), and ankylosing spondylitis (AS)]. They identified several biomarkers associated with disease severity, drug-induced effects, and treatment response. Their findings provide insights into apremilast's mechanism of action and pave the way for developing future therapeutics.

Biomarkers: Guiding the Path to Personalized Medicine

This study underscores the crucial role of biomarkers in tailoring treatments to individual patients. By identifying biomarkers associated with disease severity, drug response, and treatment outcomes, researchers can develop more personalized and effective therapies. It's like navigating a vast desert, where using a compass and landmarks can lead you to your desired destination. This research provides valuable insights into the potential of biomarkers to revolutionize healthcare and optimize patient outcomes.

The Promise of Precision Medicine in the Realm of Inflammatory Diseases

This study highlights the growing field of [precision medicine] and its potential to transform the treatment of inflammatory diseases like psoriasis and psoriatic arthritis. By identifying biomarkers that predict treatment response and disease progression, researchers can develop more targeted therapies, improving patient outcomes and minimizing side effects. It's like using a map to navigate a desert, where understanding the terrain helps you choose the safest and most efficient route. This research offers a glimpse into the future of inflammatory disease management, where personalized care will be the norm.

Dr. Camel's Conclusion

This study delves into the world of biomarkers and their potential to revolutionize the treatment of inflammatory diseases like psoriasis and psoriatic arthritis. The findings suggest that biomarkers can be used to personalize treatment, predict response, and guide the development of new therapies. It's like using a compass and landmarks to navigate a vast desert, leading you to your desired destination. This research offers exciting possibilities for the future of precision medicine, where treatments are tailored to individual needs, maximizing patient outcomes and improving overall health.
Date :
  1. Date Completed 2020-11-19
  2. Date Revised 2021-01-16
Further Info :

Pubmed ID

31953524

DOI: Digital Object Identifier

PMC6969165

Related Literature

Article Analysis
・Effects of apremilast
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.